A pharmacological overview of aprepitant for the prevention of postoperative nausea and vomiting.

Abstract

INTRODUCTION:

Post-operative nausea and vomiting (PONV) affects 30% of all patients undergoing surgery and up to 80% of high-risk patients. Antiemetics for PONV prophylaxis target a variety of receptor systems, with varying degrees of efficacy and side effect profile. Neurokinin -1 receptor antagonists are the most recent class of compounds investigated for PONV prophylaxis, with aprepitant being the only one currently approved for this indication.

AREAS COVERED:

This review covers the pathophysiology of PONV, current recommendations for PONV prophylaxis, pharmacokinetics, and pharmacodynamics of aprepitant, and the evidence for its efficacy in the management of PONV as a single agent and in combination therapy.

EXPERT OPINION:

Aprepitant is effective for PONV prophylaxis. It has superior antivomiting efficacy, long half-life, and favorable side effect profile. Data on antiemetic combinations involving aprepitant are limited, and it is not clear if the addition of other antiemetics to aprepitant results in improved PONV prophylaxis. The oral route of administration of aprepitant is a potential limitation in a busy clinical practice. However, the recent approval of an intravenous formulation could provide a more convenient route of administration. Aprepitant remains more expensive than other antiemetics, and there are no studies assessing the cost effectiveness of its use.

• Authors: Andrew Padilla, Ashraf S Habib
• Journal: Expert review of clinical pharmacology (Expert Rev Clin Pharmacol) 2023 Jan-Jun Vol. 16 Issue 6 Pg. 491-505 ISSN: 1751-2441 [Electronic] England
• PMID: 37128935 (Publication Type: Review, Journal Article)

Chemical References

• Aprepitant
• Antiemetics
• Morpholines
• Neurokinin-1 Receptor Antagonists

Topics

• Humans
• Aprepitant (pharmacology)
• Antiemetics (adverse effects)
• Postoperative Nausea and Vomiting (prevention & control, drug therapy)
• Morpholines (adverse effects)
• Vomiting (chemically induced)
• Neurokinin-1 Receptor Antagonists (adverse effects)